# Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

> **NCT03534323** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 55 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Richter Syndrome

## Interventions

- **DRUG:** Duvelisib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03534323
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-07-12
- **Primary completion:** 2024-12-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03534323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03534323, "Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03534323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*